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Background
Vesigenurtacel-L is an allogeneic cell-based therapeutic
cancer vaccine that was selected based on its expression
of a range of tumor antigens (surviving, LAGE-1,
MAGE-A3, MAGE-A11, PRAME and others) that are
known to be expressed amongst a high proportion of
primary bladder tumors. The parental cell line was
transfected with an engineered secretable heat shock
protein, gp96-Ig, which functions dually as an antigen
delivery vehicle and adjuvant. Importantly, our immune
systems evolved to screen for extracellular gp96 as a
defense mechanism against intracellular pathogens, and
this mechanism of immune activation preferentially sti-
mulates activation of CD8+ cytotoxic T cells through
the antigen cross-presentation pathway. Thus, combina-
tion therapy with Vesigenurtacel-L is proposed to acti-
vate patient CD8+ T cell responses against a variety of
bladder tumor antigens, which may provide additional
benefit in combination with a local inflammatory ther-
apy such as BCG to prevent recurrence and eliminate
minimal residual disease following initial surgery.
Methods
This is a Phase I/II study of 84 patients with non-muscle
invasive bladder cancer who have undergone TURBT, are
candidates for BCG treatment, are judged to be at an
increased risk for recurrence, and are either BCG naïve or
have completed previous BCG treatment >12 months
prior to the most recent TURBT. Nine patients will be
treated in the Phase I portion with monotherapy Vesigen-
urtacel-L (106 cells per dose, 12 weekly doses followed by
3 monthly doses) after induction BCG. In the Phase II por-
tion, 75 patients will be randomized 1:1:1 to one of two
doses of Vesigenurtacel-L (either 106 or 107 cells/dose) or
placebo in combination with 6 weeks of induction BCG,
followed by 6 weeks of monotherapy Vesigenurtacel-L in
the induction Phase. Maintenance treatment in combina-
tion with BCG will continue in patients without evidence
of disease for 3 courses of 3-weekly treatments at the
following time points relative to the initial TURBT: 3
months, 6 months, and 12 months. The primary endpoint
in Phase I is safety; the Phase II primary endpoint is 1-year
recurrence-free survival. Secondary efficacy evaluations
include determination of recurrence and progression
at various time points, analyses of immunologic response
in peripheral blood, and antigen expression analysis in tis-
sue. Clinical trial information: NCT02010203.
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